Bruce Hammock, Founder and CEO. Dr. Hammock is a Distinguished Professor at the University of California, Davis. Dr. Hammock was elected as a member to the National Academy of Sciences, US (1999). He has over 30 years of extensive experience in the field of eicosanoids that yielded over 800 publications and 100 issued patents on synthesis, pharmacology and biological action of eicosanoids and soluble epoxide hydrolase inhibitors.
Dr. William Schmidt, Clinical Development Dr. Schmidt is head of NorthStar Consulting, LLC, which specializes in providing advice on preclinical and clinical studies of novel analgesic drugs. He is the Parliamentarian and a Past-President of the Eastern Pain Association, and has over 25 years of pharmaceutical experience specifically in the development of novel analgesic drugs. Dr. Schmidt currently sits on Scientific Advisory Boards of 1 academic laboratory and 4 biotech companies.
Dr. Alan Buckpitt, Vice President of Pharmacology Dr. Buckpitt recently retired as a Professor at the University of Califorania, Davis. He received his MS and Ph.D. degrees in Pharmacology from Indiana University and spent eighteen months as a postdoctoral fellow in the Laboratory of Chemical Pharmacology, NHLBI (with Dr. Jerry Mitchell); two years as a postdoctoral fellow in the Laboratory of Clinical Pharmacology, National Cancer Institute (with Dr. Michael Boyd). Dr. Buckpitt specializes in the areas of pharmacokinetics as well as absorption, distribution, metabolism, and excretion.
Dr. Karen Wagner, Principal Scientist Dr. Wagner is an experienced pharmacologist with a background in investigating the role of sEH inhibition in neurobiology. She has extensive experience with animal behavior and in vivo experimentation that makes her very valuable for all the preclinical experiments. Cindy McReynolds, Senior Project Manager Mrs. McReynolds specializes in Project Management for start-up and semi-virtual biotech companies. She managed the preclinical efforts at Miikana that resulted in the identification of a small molecule IND candidate that is currently in phase 2 clinical trials. She also managed the research efforts from IND-enabling studies through Phase II clinical trials at Arete Therapeutics.
Natalia Vasylieva, PhD, Project Manager Dr. Vasylieva received her PhD in Micro and Nanotechnologies. She brings expertise in managing scientific collaborations with federal and private agencies as well as international collaborators. Her projects have lead to patent applications and generation of over $2.5M in additional funding.
Mike Gilson, MBA, Business Development Mr. Gilson has had a rather extensive (and fun) career building and sustaining companies serving global customers in a diverse range of functions including strategic planning, operations, finance, global business development, marketing, and product innovation and launch. He excels as an innovative strategy and operations leader with a strong finance and management background. He currently serves as a Trustee on the UC Davis Foundation and as Board Chair of the UC Davis Library Foundation.
Gilles Attia, J.D., LL.M., Legal Advisor Mr. Attia is a managing partner at DLA Piper and advises high-growth companies and investors in private and public financings, technology and merger and acquisition transactions. He previously served as a senior attorney in the Office of the General Counsel of the Securities and Exchange Commission in Washington, DC and, during the past 30 years, he has also taught courses in federal securities regulation, corporate finance and advanced business planning as an adjunct professor of law at Pacific McGeorge. Mr. Attia serves as the chair of the Dean's Leadership Council of the College of Biological Sciences of UC Davis.